Clinical Scorecard: Economic Evaluation of Smoking Cessation Strategies within Lung Cancer Screening Programs

At a Glance

Key Highlights

• Over 80% of lung cancer cases are attributable to cigarette smoking.
• More than 13 million US adults qualify for LDCT screening under updated USPSTF criteria.
• The SCALE Collaboration assesses the effectiveness of smoking cessation interventions in LDCT settings.
• Interventions include counseling and pharmacotherapy with varying intensities.
• Economic evaluations link trial data to microsimulation models for long-term outcomes.

Guideline-Based Recommendations

Diagnosis

• Annual LDCT screening for eligible adults with a substantial smoking history.

Management

• Recommend cessation to every adult who uses tobacco.
• Offer combined behavioral counseling and FDA-approved pharmacotherapy.

Monitoring & Follow-up

• Assess self-reported 7-day point prevalence abstinence at specified follow-up intervals.

Risks

• Uncertainty about the efficacy and cost-effectiveness of various smoking cessation strategies.

Patient & Prescribing Data

Individuals who smoke and meet USPSTF eligibility criteria for lung cancer screening.

Interventions incorporate counseling and pharmacotherapy, with intensity categorized for cross-trial comparability.

Clinical Best Practices

• Incorporate evidence-based cessation support into LDCT screening.
• Utilize a combination of counseling and pharmacotherapy for smoking cessation.

Related Resources & Content

• USPSTF Recommendations
• SCALE Collaboration
• CISNET Models